SEPN
vs
S&P 500
SEPN
S&P 500
Over the past 12 months, SEPN has underperformed S&P 500, delivering a return of +9% compared to the S&P 500's +14% growth.
Stocks Performance
SEPN vs S&P 500
Performance Gap
SEPN vs S&P 500
Performance By Year
SEPN vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Septerna Inc
Glance View
Septerna, Inc. is a clinical-stage biotechnology company, which engages in pioneering a new era of G protein-coupled receptor oral small molecule drug discovery powered by proprietary Native Complex PlatformTM. The company is headquartered in South San Francisco, California and currently employs 73 full-time employees. The company went IPO on 2024-10-25. The firm is developing G protein-coupled receptor (GPCR) oral small-molecule drug discovery powered by its proprietary Native Complex Platform. Its pipeline of product candidates is focused on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Its industrial-scale Native Complex Platform is designed to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists, and allosteric modulators, to achieve desired therapeutic effects. The company is advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with significant unmet needs. The company is focused in major therapeutic areas, such as neurology, women’s health, cardiovascular, and respiratory disease.
